Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.

Autor: Giannoudis A; Department of Molecular and Clinical Cancer Medicine, The Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK., Malki MI; Department of Molecular and Clinical Cancer Medicine, The Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK., Rudraraju B; Department of Molecular and Clinical Cancer Medicine, The Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK.; Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, London, UK., Mohhamed H; Cancer Early Detection Advanced Research Center, Oregon Health and Science University, Knight Cancer Institute School of Medicine, Portland, USA., Menon S; Cancer Research UK, Cambridge Research Institute, University of Cambridge, Cambridge, UK., Liloglou T; Department of Molecular and Clinical Cancer Medicine, The Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK., Ali S; Department of Surgery and Cancer, Imperial College London, Faculty of Medicine, London, UK., Carroll JS; Cancer Research UK, Cambridge Research Institute, University of Cambridge, Cambridge, UK., Palmieri C; Department of Molecular and Clinical Cancer Medicine, The Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool, L69 3GE, UK. c.palmieri@liverpool.ac.uk.; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK. c.palmieri@liverpool.ac.uk.

Publikováno v: Breast cancer research : BCR [Breast Cancer Res] 2020 Nov 16; Vol. 22 (1), pp. 126. Date of Electronic Publication: 2020 Nov 16.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative Breast Cancer.

Autor: Wang, Shih-Ho¹ (AUTHOR), Yeh, Cheng-Hsi¹ (AUTHOR), Wu, Chia-Wei² (AUTHOR) snoopy79101@gmail.com, Hsu, Chia-Yi³ (AUTHOR) husonweihsu@hotmail.com, Tsai, Eing-Mei³ (AUTHOR), Hung, Chao-Ming⁴ (AUTHOR), Wang, Yi-Wen² (AUTHOR) ywwang0228@gmail.com, Hsieh, Tsung-Hua² (AUTHOR) ed111945@edah.org.tw

Publikováno v: International Journal of Molecular Sciences. Apr2024, Vol. 25 Issue 7, p3906. 13p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.

Autor: Zwart W; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. c.palmieri@liverpool.ac.uk w.zwart@nki.nl., Flach KD; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Rudraraju B; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom., Abdel-Fatah TM; Clinical Oncology Department, Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom., Gojis O; Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, London, United Kingdom., Canisius S; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Moore D; Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom., Nevedomskaya E; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Opdam M; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Droog M; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Chan S; Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, London, United Kingdom., Shaw J; Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom., Ellis IO; Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, United Kingdom., Coombes RC; Clinical Oncology Department, Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom., Carroll JS; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom., Ali S; Clinical Oncology Department, Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom., Palmieri C; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom. Liverpool and Merseyside Academic Breast Unit, The Linda McCartney Centre, Royal Liverpool University Hospital, Liverpool, United Kingdom. Academic Department of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom. c.palmieri@liverpool.ac.uk w.zwart@nki.nl.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Jan 15; Vol. 22 (2), pp. 479-91. Date of Electronic Publication: 2015 Sep 14.